Meticillin-resistant Staphylococcus aureus

被引：128

作者：

Boyce, JM ^{[1
]}

Cookson, B

Christiansen, K

Hori, S

Vuopio-Varkila, J

Kocagöz, S

Öztop, AY

Christiansen, K

Hori, S

Vuopio-Varkila, J

Kocagöz, S

Öztop, AY

Vandenbroucke-Grauls, CMJE

Harbarth, S

Pittet, D

机构：

[1] Hosp St Raphael, Infect Dis Sect, New Haven, CT USA

[2] Hlth Protect Agcy, Lab Healthcare Associated Infect, London, England

[3] Curtin Univ Technol, Dept Microbiol & Infect Dis, Perth, WA 6001, Australia

[4] Curtin Univ Technol, Sch Biomed Sci, Perth, WA 6001, Australia

[5] Juntendo Univ, Grad Sch Med, Dept Infect Control Sci, Tokyo, Japan

[6] Natl Publ Hlth Inst, Hosp Bacteria Lab, Dept Bacterial & Inflammatory Dis, SF-00300 Helsinki, Finland

[7] Yeditepe Univ, Fac Med, Dept Clin Microbiol & Infect Dis, Istanbul, Turkey

[8] Cumhuriyet Univ, Fac Med, Dept Microbiol & Clin Microbiol, Sivas, Turkey

[9] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands

[10] Vrije Univ Amsterdam, Med Ctr, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands

[11] Univ Hosp Geneva, Dept Internal Med, Infect Control Program, Geneva, Switzerland

来源：

LANCET INFECTIOUS DISEASES | 2005年 / 5卷 / 10期

关键词：

D O I：

10.1016/S1473-3099(05)70243-7

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Meticillin was introduced in 1959 to treat infections caused by penicillin-resistant Staphylococcus aureus. In 1961 there were reports from the UK of S aureus isolates that had acquired resistance to meticillin (meticillin-resistant S aureus, MRSA). Similar MRSA isolates were soon found in other European countries, and later from Japan, Australia, and the USA. Today MRSA is a major cause of hospital-acquired infections, and a serious public-health concern. In this forum, we present different perspectives from across the globe to better understand the complexity of the problem, and examine the challenges that individual countries face in trying to control the spread of MRSA.

引用

页码：653 / 663

页数：11

共 54 条

[1]

AKATA F, 2001, ANTIBIYOTIK KEMOTERA, V15, P391

[2]

Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6

[3]

Biant LC, 2004, BRIT MED J, V329, P149

[4] Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002) [J].